Source: International Congress 2015 – New data on established treatments for asthma and COPD
Disease area: Airway diseases

Abstract

Background. Our understanding of chronic obstructive pulmonary disease (COPD) has changed over the past two decades. We have moved from an airflow limitation-centric view to the recognition that COPD is a multicomponent disease with structural and functional lung effects. Roflumilast and its main metabolite roflumilast N-oxide are selective PDE4 inhibitors which act to decrease immune and inflammatory cell activation.Aim of the study. To determine the levels of collagen type IV in bronchoalveolar fluid (BALF) before and after 180-days treatment with PDE-4 inhibitor roflumilast.Materials and methods: The levels of collagen-IV were investigated in 61 patients with severe COPD in BALF by ELISA with "StatFax 303 Plus" using «Human collagen alpha- 4 (IV) chain (COL4A4) reagents before and after 180 days treatment with roflumilast 500 mcg, 1 time per day.Results of the study: The use of maintenance therapy of COPD at the and of 180-days treatment without roflumilast showed slight improvement in collagen-IV concentration. The levels of collagen-IV decreased after 180-days therapy in 3.54 times due to the long-term beneficial effects of roflumilast as a part of maintenance therapy.Conclusions. The identification of inflammatory mediators, is important for the development of anti-inflammatory treatments that may reduce the inflammation and the clinical symptoms of COPD.


Rating:

Share or cite this content

Citations should be made in the following way:
Iryna Savelikhina (Ivano-Frankivsk, Ukraine), Mykola Ostrovskyy, Oleksandr Varunkiv, Iryna Savelikhina, Mariana Kulynych-Miskiv. The role of determining the levels of collagen type IV in the management of patients with severe chronic obstructive pulmonary disease – Focus on roflumilast. Eur Respir J 2015; 46: Suppl. 59, 1007

Member's Comments

No comment yet.

Related content which might interest you: Effect of long-term treatment with fenspiride on clinical and functional status of patients with chronic obstructive pulmonary disease Source: Annual Congress 2013 –COPD biomarkers Year: 2013 PPAR-alpha agonist (fenofibrate) therapy in exacerbation control of chronic obstructive pulmonary disease of severe stage Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014 Detection of chronic obstructive pulmonary disease (COPD) in patients with cardio-vascular system pathology Source: Annual Congress 2013 –COPD treatment and others Year: 2013 Survivin in patients with chronic obstructive pulmonary disease Source: International Congress 2015 – Monitoring and phenotyping COPD Year: 2015 Comparison of blood eosinophils and plasma periostin in stable and non-stable chronic obstructive pulmonary disease: How we can improve the management of our patients Source: International Congress 2016 – Biomarkers and phenotypes of COPD Year: 2016 The economical effect of inhaler in patients with early chronic obstructive pulmonary disease Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis Year: 2015 Effects of pulmonary rehabilitation in patients with severe COPD in comparison to patients with severe interstitial lung disease Source: Annual Congress 2013 –The best posters in pulmonary rehabilitation Year: 2013 The role of IFN-γ in severe COPD patients with anamnestic viral-induced exacerbations before and after roflumilast treatment Source: International Congress 2016 – Translational studies in lung disease Year: 2016 Can roflumilast improve clinical outcomes in moderate-to-severe chronic obstructive pulmonary disease? A meta-analysis Source: International Congress 2016 – COPD diagnosis and management Year: 2016 Regional differences in the treatment of patients with moderate COPD enrolled in a global clinical trial Source: Annual Congress 2006 - Recent advances in the treatment of COPD Year: 2006 The systemic inflammation and factors of coagulation in patients with chronic obstructive pulmonary disease (COPD) Source: International Congress 2014 – COPD markers Year: 2014 Current maintenance treatment of chronic obstructive pulmonary disease in China Source: International Congress 2014 – Respiratory disease within hospital-based populations Year: 2014 Effects of pulmonary rehabilitation on exacerbation number and severity in people with chronic obstructive pulmonary disease (COPD) Source: International Congress 2016 – Hospitalisation and comorbidities in chronic lung diseases Year: 2016 Guidelines versus clinical practice in the treatment of chronic obstructive pulmonary disease Source: Eur Respir J 2001; 18: 903-908 Year: 2001 The effectiveness of anti-inflammatory therapy for chronic obstructive pulmonary disease complicated by ischemic heart disease (new medication - new opportunities) Source: International Congress 2014 – Comorbidities Year: 2014 Quantify comorbidities burden of chronic obstructive pulmonary disease patients using medication regimen complexity index Source: International Congress 2016 – Novel avenues in the treatment of COPD I Year: 2016 Measurement properties of exacerbations of chronic pulmonary disease tool (EXACT) in a clinical trial of patients with moderate to severe COPD Source: Annual Congress 2013 –Monitoring symptoms and quality of life Year: 2013 The effect of statin therapy in patients with chronic obstructive airway disease Source: International Congress 2015 – COPD: notable points Year: 2015 Prevalence and effects of malnutrition in COPD patients referred for pulmonary rehabilitation Source: Annual Congress 2013 –The best posters in chronic care Year: 2013 The characteristic of chronic renal dysfunction in patients with chronic obstructive pulmonary disease Source: International Congress 2016 – Biomarkers and phenotypes of COPD and comorbidities Year: 2016